Paramethadione API is a synthetic oxazolidinedione compound that was historically used as an anticonvulsant, particularly for the management of absence seizures. It is chemically identified as 5-ethyl-3,5-dimethyl-1,3-oxazolidine-2,4-dione. Paramethadione has the molecular formula C7H11NO3, molecular weight 157.17 g/mol, and CAS Number 115-67-3. These identity and molecular-property values are confirmed by PubChem and the NIST Chemistry WebBook.
Paramethadione belongs to the oxazolidinedione class of anticonvulsant compounds. It is structurally related to trimethadione and is historically associated with treatment of absence-type seizures. PubChem identifies Paramethadione as an anticonvulsant and records its ATC classification as N03AC01.
PubChem and NIST both confirm the CAS Number 115-67-3, molecular formula C7H11NO3, and molecular weight approximately 157.17 g/mol.
Paramethadione was developed as an anticonvulsant and historically used for the control of absence seizures. It belongs to the same broad oxazolidinedione family as trimethadione.
Potential pharmaceutical and research applications include:
PubChem records its therapeutic classification under anticonvulsants and describes its historical use for refractory absence seizures.
Paramethadione contains an oxazolidine-2,4-dione ring with ethyl and methyl substitution. Its IUPAC name is 5-ethyl-3,5-dimethyl-1,3-oxazolidine-2,4-dione.
The compound has three oxygen atoms and one nitrogen atom. Its calculated topological polar surface area is 46.6 Ų, while its reported XLogP3-AA value is 0.8.
NIST provides spectroscopic records for Paramethadione, including infrared and mass-spectral information, supporting its use as an analytically identifiable chemical substance.
Historical reference data describe Paramethadione as a clear, colorless liquid with a fruity, ester-like odor. NIST reports a molecular weight of 157.1671 g/mol and a boiling point of approximately 101.5°C.
Because physical-property descriptions can depend on temperature, purity and measurement conditions, a universal pharmaceutical release specification should not be inferred from historical physical-property data.
Quality assessment of Paramethadione API can include:
NIST maintains infrared and mass-spectral records for Paramethadione, providing useful analytical identification references.
Paramethadione API manufacturing should be conducted under appropriate pharmaceutical quality systems when the material is intended for regulated pharmaceutical use. Control of starting materials, reaction intermediates, purification, final processing and packaging is important for consistent API quality.
A pharmaceutical specification should establish validated analytical methods for identity, assay, impurities and other applicable quality attributes. Since a current universal USP numerical release specification was not verified from the sources reviewed, unsupported numerical limits should not be presented as official compendial requirements.
Paramethadione Bulk API may be relevant to pharmaceutical research, analytical reference applications and specialized API development. Procurement documentation should clearly identify the substance as Paramethadione and include CAS 115-67-3, C7H11NO3, and molecular weight 157.17 g/mol.
The identity should not be confused with Trimethadione, another oxazolidinedione anticonvulsant. Paramethadione is specifically identified by CAS 115-67-3 and the molecular structure corresponding to 5-ethyl-3,5-dimethyl-1,3-oxazolidine-2,4-dione.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 0.5% |
| Residue on Ignition | NMT 0.1% |
| Heavy Metals | NMT 20 ppm |
| pH (1% Solution) | 2.0 – 4.0 |
| Water Content | NMT 0.5% |